Positions

Overview

  • Dr. Mobley is considered an expert in proteomics by his peers, and as director of the Mass Spectrometry/Proteomics Shared Facility, continues to focus on clinical and translational proteomics applications, which include statistical analysis of high density 'omics driven data sets, and the use of systems biology applications to uncover biologically relevant pathways. He has nearly 30 years experience in academia and industry, and mass spectrometry has been a intricate part of his work experience and studies from the beginning.

    Dr. Mobley obtained his B.S. in Chemistry at Oregon State University. He obtained a Ph.D. in Medicinal Chemistry and Pharmacology from The Ohio State University with an emphasis on hormonal induced carcinogesis. Prior to joining the faculty at UAB in 2006, Dr. Mobley worked as a faculty member at UMass Medical School and also at Vanderbilt.

    In 2007, Dr. Mobley became Director of the newly formed UAB Comprehensive Cancer Center Clinical Proteomics Shared Facility, and due to the success of that facility he was asked to expand in 2009 to encompass a single campus wide MS/ Proteomics Shared Facility (MSP-SF).
  • Research Overview

  • proteomics
  • Investigator On

  • Novel Therapeutics For Acquired Thrombotic Thrombocytopenic Purpura  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2023
  • Biosynthetic Metabolic Pathway Regulation of Glioma Growth  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Racial Differences in the Natriuretic Peptide Response to Exercise and Beta-blockers  awarded by American Heart Association 2018 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Analysis Of Novel Molecular Mechanisms Regulating Expression Of The Adaptor Protein HSH2 And Class-Switched Antibody Production  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2018 - 2020
  • A Novel Role for IGF-1 Receptor in Growth Hormone Action  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2019
  • Alveolar DevMAP  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • UAB / UMN SPORE in Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2010 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2016
  • Effects of 14-3-3s on Alpha-Synuclein Release and Toxicity  awarded by American Parkinson Disease Association 2014 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Project 1  awarded by National Cancer Institute/NIH/DHHS 2010 - 2016
  • Combinational Environmental Chemicals Altering Susceptibility for Mammary Cancer  awarded by National Institute of Environmental Health Sciences/NIH/DHHS 2010 - 2016
  • Endogenous Oxalate Synthesis  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2013 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2006 - 2012
  • Education And Training

  • Doctor of Pharmacy in Medicinal/Pharmaceutical Chemistry, Ohio State University System : Columbus 2000
  • Full Name

  • James Mobley